BeyondSpring Inc. (NASDAQ:BYSI) and uniQure N.V. (NASDAQ:QURE), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring Inc.	N/A	0.00	56.85M	-2.54	0.00
uniQure N.V.	11.28M	196.89	83.30M	-2.69	0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of BeyondSpring Inc. and uniQure N.V.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring Inc.	0.00%	-219.5%	-180.8%
uniQure N.V.	-738.48%	-58.5%	-35.9%

Liquidity

The Current Ratio and a Quick Ratio of BeyondSpring Inc. are 4.4 and 4.4. Competitively, uniQure N.V. has 7.6 and 7.6 for Current and Quick Ratio. uniQure N.V.’s better ability to pay short and long-term obligations than BeyondSpring Inc.

Analyst Recommendations

BeyondSpring Inc. and uniQure N.V. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
BeyondSpring Inc.	0	0	0	0.00
uniQure N.V.	0	0	7	3.00

Competitively the consensus price target of uniQure N.V. is $77.57, which is potential 30.04% upside.

Institutional and Insider Ownership

BeyondSpring Inc. and uniQure N.V. has shares owned by institutional investors as follows: 1.4% and 78.9%. Insiders owned 77.22% of BeyondSpring Inc. shares. Comparatively, insiders own roughly 2.2% of uniQure N.V.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
BeyondSpring Inc.	4.73%	2.82%	-23.1%	-19.89%	-25.53%	-0.75%
uniQure N.V.	6.3%	73.4%	107.66%	40.7%	137.94%	106.07%

For the past year BeyondSpring Inc. had bearish trend while uniQure N.V. had bullish trend.

Summary

uniQure N.V. beats on 7 of the 10 factors BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.